<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) has provided an update. TransThera Sciences (Nanjing), Inc. has highlighted new research at the 2026 American Association for Cancer Research Annual Meeting showing that lineage plasticity, driven by convergent FGFR-JAK signaling, is a key mechanism of resistance to endocrine therapy in HR-positive breast cancer. Using single-cell transcriptomics and resistant tumor models, the company’s team identified a luminal-to-basal transition with ER and PR downregulation that arises in primary tumors and intensifies in metastases, particularly malignant pleural effusions. The preclinical data indicate that tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, can restore luminal identity and resensitize resistant HR-positive breast cancer models to endocrine therapy in vitro and in vivo, supporting dual FGFR-JAK blockade as a strategy to overcome lineage plasticity-driven resistance. This work underpins an ongoing phase II clinical trial of tinengotinib combined with endocrine therapy in advanced HR-positive breast cancer and reinforces the drug’s broader potential across solid tumors where it already holds multiple regulatory designations, bolstering TransThera’s positioning in the competitive oncology therapeutics market. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a China-based biopharmaceutical company focused on discovering and developing targeted oncology therapies, particularly multi-kinase inhibitors for solid tumors. Its lead asset tinengotinib, an NDA-stage, multi-kinase inhibitor targeting FGFRs, VEGFRs, Aurora A/B and JAK, is being evaluated globally in multiple cancer indications and holds orphan drug and fast-track designations in major markets. Average Trading Volume: 2,482,081 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$21.35B </div>

516930

159748

520500

TransThera Sciences (Nanjing), Inc. presented new research at the 2026 AACR Annual Meeting, revealing that lineage plasticity from FGFR-JAK signaling contributes to endocrine therapy resistance in HR-positive breast cancer. Their study indicates that tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, can restore luminal identity and resensitize resistant cancer models to endocrine therapy. This supports ongoing phase II trials of tinengotinib combined with endocrine therapy in advanced HR-positive breast cancer, highlighting its potential across various solid tumors and enhancing TransThera's position in the oncology market.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

TRANSTHERA-B

TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026